Publications by authors named "David Santamaria"

Claim this Profile
A
A nucleotide-independent, pan-RAS-targeted DARPin elicits anti-tumor activity in a multimodal manner.
Jonas N Kapp, Wouter P R Verdurmen, Jonas V Schaefer, Kari Kopra, Gabriela Nagy-Davidescu, David Santamaria

Mol Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cx43 enhances response to BRAF/MEK inhibitors by reducing DNA repair capacity.
Adrián Varela-Vázquez, Amanda Guitián-Caamaño, Paula Carpintero-Fernández, Alexander Carneiro-Figueira, Vanesa Álvarez

Nat Commun· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cell cycle duration determines oncogenic transformation capacity.
Danian Chen, Suying Lu, Katherine Huang, Joel D Pearson, Marek Pacal, David Santamaria

Nature· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oncogenic mutant KRAS inhibition through oxidation at cysteine 118.
Maximilian Kramer-Drauberg, Ettore Petrini, Alessia Mira, Enrico Patrucco, Rossella Scardaci, David Santamaria

Mol Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Experimental variables determine the outcome of RAS-RAS interactions.
Zhiwei Zhou, Tra Ly Nguyen, Xingxiao Li, Christel Poujol, Ewa Berlinska

J Biol Chem· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Type I interferon signaling pathway enhances immune-checkpoint inhibition in KRAS mutant lung tumors.
Fernando Fernández-García, Ana Fernández-Rodríguez, Coral Fustero-Torre, Elena Piñeiro-Yáñez, Haiyun Wang

Proc Natl Acad Sci U S A· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vivo vulnerabilities to GPX4 and HDAC inhibitors in drug-persistent versus drug-resistant BRAF lung adenocarcinoma.
Marie-Julie Nokin, Elodie Darbo, Elodie Richard, Sonia San José, Sergio de Hita

Cell Rep Med· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade.
Marie-Julie Nokin, Alessia Mira, Enrico Patrucco, Biagio Ricciuti, Sophie Cousin

Nat Commun· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel RAF-directed approaches to overcome current clinical limits and block the RAS/RAF node.
Rossella Scardaci, Ewa Berlinska, Pietro Scaparone, Sandra Vietti Michelina, Edoardo Garbo, David Santamaria

Mol Oncol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy.
Matthew Holderfield, Bianca J Lee, Jingjing Jiang, Aidan Tomlinson, Kyle J Seamon, David Santamaria

Nature· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reuniting philosophy and science to advance cancer research.
Thomas Pradeu, Bertrand Daignan-Fornier, Andrew Ewald, Pierre-Luc Germain, Samir Okasha, David Santamaria

Biol Rev Camb Philos Soc· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative Analysis and Isoform-Specific Therapeutic Vulnerabilities of KRAS Mutations in Non-Small Cell Lung Cancer.
Biagio Ricciuti, Jieun Son, Jeffrey J Okoro, Alessia Mira, Enrico Patrucco, David Santamaria

Clin Cancer Res· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How far we have come targeting BRAF-mutant non-small cell lung cancer (NSCLC).
Fabrizio Tabbò, Chiara Pisano, Julien Mazieres, Laura Mezquita, Ernest Nadal, David Santamaria

Cancer Treat Rev· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gene Expression Profiling as a Potential Tool for Precision Oncology in Non-Small Cell Lung Cancer.
Sara Hijazo-Pechero, Ania Alay, Raúl Marín, Noelia Vilariño, Cristina Muñoz-Pinedo

Cancers (Basel)· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting Infrequent Driver Alterations in Non-Small Cell Lung Cancer.
Marie-Julie Nokin, Chiara Ambrogio, Ernest Nadal, David Santamaria

Trends Cancer· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RAF1 kinase activity is dispensable for KRAS/p53 mutant lung tumor progression.
Manuel Sanclemente, Patricia Nieto, Sara Garcia-Alonso, Fernando Fernández-García, Laura Esteban-Burgos

Cancer Cell· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor regression and resistance mechanisms upon CDK4 and RAF1 inactivation in KRAS/P53 mutant lung adenocarcinomas.
Laura Esteban-Burgos, Haiyun Wang, Patricia Nieto, Jie Zheng, Carmen Blanco-Aparicio

Proc Natl Acad Sci U S A· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Squamous differentiation requires G2/mitosis slippage to avoid apoptosis.
Natalia Sanz-Gómez, Isabel de Pedro, Beatriz Ortigosa, David Santamaría, Marcos Malumbres

Cell Death Differ· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of DDR1 enhances in vivo chemosensitivity in KRAS-mutant lung adenocarcinoma.
Marie-Julie Nokin, Elodie Darbo, Camille Travert, Benjamin Drogat, Aurélie Lacouture

JCI Insight· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Meeting report - first discoidin domain receptors meeting.
Patrick Auguste, Birgit Leitinger, Christelle Liard, Virginie Rocher, Laurent Azema, David Santamaria

J Cell Sci· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Myc stimulates cell cycle progression through the activation of Cdk1 and phosphorylation of p27.
Lucía García-Gutiérrez, Gabriel Bretones, Ester Molina, Ignacio Arechaga, Catherine Symonds

Sci Rep· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A putative role for Discoidin Domain Receptor 1 in cancer chemoresistance.
Chiara Ambrogio, Elodie Darbo, Sam W Lee, David Santamaría

Cell Adh Migr· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular determinants of acquired resistance to BRAF inhibition in human lung cancer.
Carlo Lucchesi, Benjamin Drogat, David Santamaria, Sophie Cousin, Antoine Italiano

Lung Cancer· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS.
Chiara Ambrogio, Jens Köhler, Zhi-Wei Zhou, Haiyun Wang, Raymond Paranal

Cell· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Braf kinase-inactive mutant induces lung adenocarcinoma.
Patricia Nieto, Chiara Ambrogio, Laura Esteban-Burgos, Gonzalo Gómez-López, María Teresa Blasco

Nature· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis